Jon Coleman Sells 4,912 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Jon Coleman sold 4,912 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total value of $358,576.00. Following the completion of the sale, the executive vice president directly owned 100,361 shares of the company’s stock, valued at $7,326,353. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jon Coleman also recently made the following trade(s):

• On Thursday, June 4th, Jon Coleman sold 4,911 shares of DexCom stock. The shares were sold at an average price of $74.13, for a total value of $364,052.43.

DexCom Trading Up 0.4%

NASDAQ DXCM opened at $72.86 on Friday. The firm has a market capitalization of $28.11 billion, a P/E ratio of 31.14, a PEG ratio of 1.14 and a beta of 1.45. The business has a fifty day simple moving average of $64.83 and a 200 day simple moving average of $66.98. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 EPS. On average, analysts predict that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Avidity Partners Management LP purchased a new position in shares of DexCom during the 1st quarter valued at $5,652,000. Glenmede Trust Co. NA lifted its position in shares of DexCom by 36.7% during the 1st quarter. Glenmede Trust Co. NA now owns 394,751 shares of the medical device company’s stock valued at $24,790,000 after buying an additional 105,928 shares during the last quarter. Wellington Grp LLC lifted its position in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after buying an additional 475 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of DexCom by 32.3% during the 1st quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock valued at $166,077,000 after buying an additional 645,534 shares during the last quarter. Finally, Centaurus Financial Inc. purchased a new position in shares of DexCom during the 1st quarter valued at $943,000. Institutional investors own 97.75% of the company’s stock.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom announced it will highlight new clinical findings, product advancements, and strategic initiatives at ADA 2026, reinforcing its case for broader CGM adoption and earlier-stage diabetes intervention. Article: Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
• Positive Sentiment: Recent commentary remained constructive, with analysts and market coverage noting DexCom’s strong Q1 momentum, global CGM growth potential, and expanding international demand, which may help support the stock. Article: Here’s Why You Should Retain DexCom Stock in Your Portfolio
• Positive Sentiment: DexCom also said it plans to acquire wellness tracking company Nutrisense and launch an enhanced Stelo app, a move that could broaden its consumer health footprint and create new engagement opportunities. Article: Dexcom to acquire wellness tracking company Nutrisense, launch enhanced Stelo app
• Neutral Sentiment: DexCom EVP Jon Coleman sold shares in two transactions under a pre-arranged 10b5-1 plan. While the sales were disclosed as routine, insider selling can still weigh on sentiment. Article: SEC Form 4 filing
• Neutral Sentiment: Separate market commentary noted DexCom has lagged the Dow over the past year, even as analysts remain bullish on its longer-term outlook. Article: Is DexCom Stock Underperforming the Dow?

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of analyst reports. Truist Financial reissued a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Canaccord Genuity Group set a $82.00 price objective on DexCom and gave the company a “buy” rating in a research note on Monday, May 18th. BTIG Research restated a “buy” rating and issued a $85.00 price objective on shares of DexCom in a research note on Monday, March 9th. TD Cowen reduced their price objective on DexCom from $84.00 to $75.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of DexCom in a research note on Monday, June 1st. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $82.63.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.